Related Experiment Video
Updated: Feb 18, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Identification of pyruvate dehydrogenase kinase 1 inhibitors with anti-osteosarcoma activity
Aiping Fang1, Huiqiang Luo2, Liping Liu3
1West China School of Public Health/No. 4 West China Teaching Hospital, Sichuan University, Chengdu 610041, PR China; State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, PR China.
Abstract:
Overexpression of pyruvate dehydrogenase kinases (PDKs), especially PDK1 has been observed in a variety of cancers. Thus, targeting PDK1 offers an attractive opportunity for the development of cancer therapies. In this letter, we reported the identification of two novel PDK1 inhibitors as anti-osteosarcoma agents. We found that TM-1 and TM-2 inhibited PDK1 with the IC50 values of 2.97 and 3.41 μM, respectively. Furthermore, TM-1 and TM-2 dose-dependently reduced phosphorylation of pyruvate dehydrogenase complex in MG-63 osteosarcoma cells. Finally, TM-1 and TM-2 were found to inhibit the proliferation of MG-63 cells with the EC50 values of 14.5, and 11.0 μM, respectively, meaning TM-1 and TM-2 could be promising leads for the discovery of potent PDK1 inhibitors.
Insights
Two novel compounds, TM-1 and TM-2, show promise as anti-osteosarcoma agents by inhibiting pyruvate dehydrogenase kinase 1 (PDK1). These inhibitors effectively reduced cancer cell proliferation, indicating potential for new cancer therapies.
Area of Science:
- Biochemistry
- Oncology
- Medicinal Chemistry
Background:
- Pyruvate dehydrogenase kinases (PDKs), particularly PDK1, are overexpressed in various cancers.
- Targeting PDK1 presents a viable strategy for developing novel cancer therapeutics.
Purpose of the Study:
- To identify and characterize novel PDK1 inhibitors with potential anti-osteosarcoma activity.
- To evaluate the efficacy of these inhibitors in osteosarcoma cell lines.
Main Methods:
- In vitro inhibition assays to determine IC50 values for PDK1 inhibition by TM-1 and TM-2.
- Western blot analysis to assess the effect of TM-1 and TM-2 on pyruvate dehydrogenase complex phosphorylation in MG-63 cells.
- Cell proliferation assays to determine EC50 values for TM-1 and TM-2 in MG-63 osteosarcoma cells.
Main Results:
- TM-1 and TM-2 demonstrated significant inhibition of PDK1 with IC50 values of 2.97 μM and 3.41 μM, respectively.
- Both compounds dose-dependently reduced the phosphorylation of the pyruvate dehydrogenase complex in MG-63 osteosarcoma cells.
- TM-1 and TM-2 effectively inhibited MG-63 cell proliferation with EC50 values of 14.5 μM and 11.0 μM, respectively.
Conclusions:
- TM-1 and TM-2 are identified as potent PDK1 inhibitors with significant anti-proliferative effects on osteosarcoma cells.
- These novel compounds represent promising lead candidates for the development of targeted therapies against osteosarcoma.
